Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Proteome Sciences plc    PRM   GB0003104196

Delayed Quote. Delayed  - 09/28 05:35:00 pm
10.875 GBp   -1.14%
09/22 PROTEOME SCIENC : Spectrometry Technique Dramatically Enhances Detec..
09/20 PROTEOME SCIENC : Stacking the odds in Alzheimer's Disease Drug Deve..
09/15 PROTEOME SCIENC : Expects Good Revenue Growth As Loss Widens
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/22/2016 09/23/2016 09/26/2016 09/27/2016 09/28/2016 Date
11.625(c) 11.375(c) 11.25(c) 11(c) 10.875 Last
1 483 411 123 200 58 896 87 434 182 826 Volume
+14.81% -2.15% -1.10% -2.22% -1.14% Change
More quotes
Financials ( GBP)
Sales 2016 3,00 M
EBIT 2016 -2,60 M
Net income 2016 -2,50 M
Debt 2016 8,60 M
Yield 2016 -
Sales 2017 -
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 -
Capi. / Sales2016 11,2x
Capi. / Sales2017 -
Capitalization 25,1 M
More Financials
Company
Proteome Sciences Plc engages in applied proteomics and peptidomics services and applications.It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development.It focuses on developing proprietary protein biomarkers for neurological diseases,... 
More about the company
Latest news on PROTEOME SCIENCES PLC
09/22 PROTEOME SCIENCES : Spectrometry Technique Dramatically Enhances Detection of Ke..
09/20 PROTEOME SCIENCES : Stacking the odds in Alzheimer's Disease Drug Development #W..
09/15 PROTEOME SCIENCES : Expects Good Revenue Growth As Loss Widens
09/12PROTEOME SCIENCES PLC : half-yearly earnings release
07/28 PROTEOME SCIENCES : Sales Momentum To Continue After Strong First Half
07/28 PROTEOME SCIENCES : Trading Update and Notice of Results
06/24 PROTEOME SCIENCES : AGM Statement and Result of AGM
06/01 PROTEOME SCIENCES : Publication of Annual Reports and Accounts 2015
06/01 PROTEOME SCIENCES : CEO Appointment
05/18 PROTEOME SCIENCES : Appoints New CEO As Annual Loss Narrows
More news
Sector news : Bio Therapeutic Drugs
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
Advertisement
Chart PROTEOME SCIENCES PLC
Duration : Period :
Proteome Sciences plc Technical Analysis Chart | PRM | GB0003104196 | 4-Traders
Full-screen chart
Technical analysis trends PROTEOME SCIENCES...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts 0
Average target price 0,38  GBP
Spread / Average Target 245%
Consensus details
Managers
NameTitle
Jeremy Rupert Michael Haigh Chief Executive Officer & Director
Christopher D. J. Pearce Executive Chairman
Ian H. Pike Chief Operating Officer & Executive Director
Geoffrey John Ellis Secretary, Executive & Finance Director
Malcolm Ward Chief Technical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOME SCIENCES PLC-30.16%33
AMGEN, INC.5.73%129 863
GILEAD SCIENCES, INC.-21.68%106 391
CELGENE CORPORATION-10.32%82 402
REGENERON PHARMACEUTIC..-22.37%42 552
VERTEX PHARMACEUTICALS..-29.17%21 876
More Results